CryoPort Inc (CYRX)
NASDAQ:CYRX
Top Page
CryoPort
(NASDAQ:CYRX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$10.00
▲(8.58% Upside)
Action:ReiteratedDate:03/06/26
The score is held back primarily by weak underlying financial quality (ongoing operating losses and negative, deteriorating cash flow) and bearish technical momentum. These are partially offset by a low P/E valuation and a positive earnings-call outlook with growth guidance and expected adjusted EBITDA improvement into H2 2026.
Positive Factors
Market position in cell & gene therapy
Sustained double-digit growth in commercial cell & gene shipments demonstrates CryoPort's durable niche advantage in highly regulated, high-value logistics. As therapies scale commercially, recurring per-shipment fees and operational expertise create sticky revenue and higher lifetime value per customer.
Negative Factors
Weak operating cash flow
Persistent negative operating and free cash flow indicates the business still consumes capital despite accounting profits. That structural cash gap increases reliance on external financing or asset monetizations, raising execution and dilution risk until cash generation turns sustainably positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Market position in cell & gene therapy
Sustained double-digit growth in commercial cell & gene shipments demonstrates CryoPort's durable niche advantage in highly regulated, high-value logistics. As therapies scale commercially, recurring per-shipment fees and operational expertise create sticky revenue and higher lifetime value per customer.
Read all positive factors
CryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$482.11M
Dividend YieldN/A
Average Volume (3M)690.07K
Price to Earnings (P/E)6.8
Beta (1Y)1.20
Revenue Growth-15.86%
EPS Growth66.42%
CountryUS
Employees1,090
SectorIndustrials
Sector Strength72
IndustryIntegrated Freight & Logistics
Share Statistics
EPS (TTM)-0.27
Shares Outstanding49,856,136
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-19.21
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda-60.50
Forecast
1Y Price Target
$12.75Price Target Upside38.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$191.84M
CryoPort Business Overview & Revenue Model
Company Description
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platfor...
How the Company Makes Money
CryoPort primarily makes money by providing end-to-end, temperature-controlled logistics services for biopharmaceutical customers, with revenue largely generated on a per-shipment and/or contracted-services basis. Key revenue streams include: (1) ...
CryoPort Key Performance Indicators (KPIs)
CryoPort Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational momentum and clear growth drivers: revenue exceeded guidance, commercial cell and gene therapy and BioStorage/BioServices posted robust double-digit gains, the clinical pipeline is deep (86 Phase III, 361 Phase II) and product innovation continues. Management improved adjusted EBITDA by $12M and expects positive adjusted EBITDA in H2 2026, while setting 2026 revenue guidance of $190M–$194M. Offsetting risks are modest near-term headwinds: slower quarterly product growth, short-term costs from expedited site buildouts, gradual realization of DHL partnership benefits, and macro/regulatory uncertainties. Overall, highlights substantially outweigh the manageable lowlights, supporting an optimistic near- to mid-term outlook.Positive Updates
Full-Year Revenue Above Guidance
Revenue from continuing operations of $176.2 million for fiscal 2025, exceeding the high end of prior guidance.
Negative Updates
Near-Term Product Growth Softening
MVE product revenue showed modest growth with 7% for the full year but only ~2% year-over-year in the fourth quarter; management now forecasts mid-single-digit growth for MVE in 2026 (7%–8%) rather than previously discussed higher ranges.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue Above Guidance
Revenue from continuing operations of $176.2 million for fiscal 2025, exceeding the high end of prior guidance.
Read all positive updates
Company Guidance
Cryoport guided full‑year 2026 revenue of $190–$194 million (midpoint ~$192M, roughly +9% vs. 2025 continuing‑operations revenue of $176.2M) and reiterated it expects to achieve positive adjusted EBITDA in the second half of 2026; management also said it anticipates ~13 BLA/MAA filings (2 already filed), 9 new therapy approvals plus 2 label/geographic expansions (with 3 customer decisions expected in March–April), noting a “spring‑loaded” clinical pipeline of 760 supported trials (86 Phase III, 361 Phase II) and 20 commercial therapies, after 2025 results that included $33.4M in commercial cell & gene therapy revenue (+29% YoY, ~20% of Q4 revenue), $47.1M in clinical trial revenue (+14% YoY), Life Sciences Services revenue +18% (BioStorage/BioServices +22%), Life Sciences Products +7%, a 47% gross margin, and a $12M year‑over‑year improvement in adjusted EBITDA.CryoPort Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
66
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 176.18M | 233.25M | 237.28M | 222.61M | 222.61M |
| Gross Profit | 83.05M | 99.33M | 103.87M | 96.58M | 96.58M |
| EBITDA | -11.65M | -66.36M | -6.19M | -248.91M | -248.91M |
| Net Income | 70.30M | -99.59M | -37.33M | -275.53M | -275.53M |
Balance Sheet | |||||
| Total Assets | 764.99M | 703.49M | 957.74M | 1.04B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 411.21M | 261.75M | 456.75M | 523.32M | 628.80M |
| Total Debt | 230.72M | 250.70M | 416.00M | 435.91M | 427.06M |
| Total Liabilities | 262.35M | 301.59M | 468.72M | 482.91M | 471.14M |
| Stockholders Equity | 502.64M | 401.90M | 489.02M | 555.84M | 641.83M |
Cash Flow | |||||
| Free Cash Flow | -25.02M | -33.58M | -45.66M | -26.05M | -16.88M |
| Operating Cash Flow | -8.58M | -16.32M | -757.00K | -1.85M | 8.13M |
| Investing Cash Flow | 250.32M | 176.81M | 36.05M | -59.68M | -469.25M |
| Financing Cash Flow | -21.07M | -161.53M | -23.80M | -39.17M | 564.34M |
CryoPort Technical Analysis
Positive
9.21
Price Trends
8.53
Positive
9.15
Positive
8.94
Positive
Market Momentum
0.27
Negative
67.78
Neutral
87.12
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 9.21 is above the 20-day moving average (MA) of 8.50, above the 50-day MA of 8.53, and above the 200-day MA of 8.94, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 67.78 is Neutral, neither overbought nor oversold. The STOCH value of 87.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CryoPort Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $18.60B | 11.18 | 14.02% | 2.98% | 12.89% | 3.12% | |
69 Neutral | $21.48B | 31.73 | 16.33% | 0.89% | -1.60% | 4.87% | |
68 Neutral | $89.26B | 22.26 | 15.76% | 1.94% | 3.09% | 14.94% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | $24.92B | 50.75 | 17.81% | ― | -0.30% | -11.02% | |
57 Neutral | $482.11M | 6.84 | 17.12% | ― | -15.86% | 66.42% | |
50 Neutral | $6.43B | 190.29 | 1.09% | ― | 16.94% | -14.01% |
* Industrials Sector Average
CYRX
CryoPort
9.64
3.98
70.32%
XPO
XPO
212.15
114.69
117.68%
FDX
FedEx
371.89
166.02
80.64%
JBHT
JB Hunt
227.61
91.29
66.97%
ZTO
ZTO Express
25.10
6.77
36.90%
GXO
GXO Logistics
56.60
22.10
64.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.